BONESUPPORT HOLDING AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0009858152
SEK
183.80
-2.7 (-1.45%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has a low Debt to Equity ratio (avg) at times

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 45.12%

 
3

The company declared negative results in Mar'25 after positive results in Dec'24

4

With ROE of 18.93%, it has a very expensive valuation with a 21.84 Price to Book Value

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 13,580 Million (Small Cap)

stock-summary
P/E

115.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.44

stock-summary
Return on Equity

18.66%

stock-summary
Price to Book

16.25

Revenue and Profits:
Net Sales:
284 Million
(Quarterly Results - Jun 2025)
Net Profit:
53 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-42.09%
0%
-42.09%
6 Months
-27.35%
0%
-27.35%
1 Year
-49.0%
0%
-49.0%
2 Years
4.49%
0%
4.49%
3 Years
116.49%
0%
116.49%
4 Years
420.68%
0%
420.68%
5 Years
142.48%
0%
142.48%

BONESUPPORT HOLDING AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
45.12%
EBIT Growth (5y)
32.98%
EBIT to Interest (avg)
-33.59
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
1.23
Tax Ratio
20.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.90%
ROE (avg)
12.58%
Valuation key factors
Factor
Value
P/E Ratio
115
Industry P/E
Price to Book Value
21.84
EV to EBIT
78.53
EV to EBITDA
78.53
EV to Capital Employed
34.61
EV to Sales
16.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
44.07%
ROE (Latest)
18.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 29.39% vs 56.55% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 93.80% vs 426.92% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "284.40",
          "val2": "219.80",
          "chgp": "29.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "66.30",
          "val2": "29.70",
          "chgp": "123.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.20",
          "chgp": "350.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "53.10",
          "val2": "27.40",
          "chgp": "93.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "233.00%",
          "val2": "135.20%",
          "chgp": "9.78%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 52.04% vs 79.77% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -45.39% vs 459.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "898.70",
          "val2": "591.10",
          "chgp": "52.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "157.70",
          "val2": "32.30",
          "chgp": "388.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "3.10",
          "chgp": "-25.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "133.80",
          "val2": "245.00",
          "chgp": "-45.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "163.50%",
          "val2": "37.50%",
          "chgp": "12.60%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
284.40
219.80
29.39%
Operating Profit (PBDIT) excl Other Income
66.30
29.70
123.23%
Interest
0.90
0.20
350.00%
Exceptional Items
-2.80
0.00
Consolidate Net Profit
53.10
27.40
93.80%
Operating Profit Margin (Excl OI)
233.00%
135.20%
9.78%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 29.39% vs 56.55% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 93.80% vs 426.92% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
898.70
591.10
52.04%
Operating Profit (PBDIT) excl Other Income
157.70
32.30
388.24%
Interest
2.30
3.10
-25.81%
Exceptional Items
0.00
0.00
Consolidate Net Profit
133.80
245.00
-45.39%
Operating Profit Margin (Excl OI)
163.50%
37.50%
12.60%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 52.04% vs 79.77% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -45.39% vs 459.24% in Dec 2023

stock-summaryCompany CV
About BONESUPPORT HOLDING AB stock-summary
stock-summary
BONESUPPORT HOLDING AB
Pharmaceuticals & Biotechnology
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Company Coordinates stock-summary
Company Details
Scheelevagen 19 , LUND None : 223 70
stock-summary
Tel: 46 46 286537046 46 2865370
stock-summary
Registrar Details